Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 19, 2017
Sunitinib toxicity management - a practical approachSandeep SehdevCurrent Oncology (Toronto, Ont.)|March 24, 2022
Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021Sandeep Sehdev, Alexandra ChambersJournal of Controlled Release : Official Journal of the Controlled Release Society|May 21, 2026
Nanomedicines from the patient perspective - 30 years after PEGylated liposomal doxorubicinLucy Wang, Sandeep Sehdev, Alvina Nadeem, et al.Current Oncology (Toronto, Ont.)|March 27, 2024
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to ActionSandeep Sehdev, Joanna Gotfrit, Martine Elias, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2013
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care systemPeter M Ellis, Sunil Verma, Sandeep Sehdev, et al.Current Oncology (Toronto, Ont.)|April 21, 2022
Access Denied? The Unintended Consequences of Pending Drug Pricing RulesAlan Kaplan, David J Stewart, Gerald Batist, et al.Current Oncology (Toronto, Ont.)|April 3, 2021
Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global PandemicTabitha Tse, Sandeep Sehdev, Jean Seely, et al.Therapeutic Advances in Medical Oncology|June 16, 2023
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigmCharlie Yang, Christine Brezden-Masley, Anil Abraham Joy, et al.Current Oncology (Toronto, Ont.)|December 22, 2022
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to ExplainDaniel Rayson, Sonal Gandhi, Anil A Joy, et al.Current Oncology (Toronto, Ont.)|May 26, 2023
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895"Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.Pageof 4